GALD GALDERMA GROUP AG

Galderma Introduces High Potency Cetaphil Serums Designed for Sensitive Skin

Galderma announced today the exclusive launch in the U.S. of its latest innovations in its Cetaphil range of products: a Vitamin C Serum and a Ceramide Serum.

In a clinical study, 95% of participants agreed the Cetaphil Vitamin C Serum continuously brightened the appearance of skin over time, 93% agreed it revealed a healthy glow day after day and 86% agreed it effectively reduced the appearance of dark spots. In another clinical study, 100% of participants agreed that the Cetaphil Ceramide Serum soothed sensitive skin and visibly improved skin texture after four weeks.

Serums have grown in popularity to rank as the preferred treatment option, making up a 33% share of facial skincare in the treatment category.1 They are praised by users as the most effective part of their skincare routine. However, a considerable part of the population still avoids using serums due to concerns around possible skin irritation.2 Galderma’s unique expertise in delivering solutions for sensitive skin, backed by Cetaphil’s heritage of more than 75 years, combined to produce these latest innovations in this sensitive skincare range.

Cetaphil Vitamin C and Ceramide Serums provide clinically proven results while targeting the skin’s moisture barrier, a frequent point of concern for people with sensitive skin. According to Spate’s 2024 Predicted Trends Report,3 skin barrier care is predicted to be one of the top skincare trends of the year. Galderma formulates its products with dermatologist-backed ingredients proven to help strengthen skin barrier function and defend against five signs of skin sensitivity: weakened skin barrier, dryness, irritation, roughness and tightness.

"we are delighted to bring this latest innovation to the U.S. market, highlighting Cetaphil’s commitment to serve the unique needs of people with sensitive skin. Our Cetaphil Vitamin C and Ceramide Serums were developed in the knowledge that while consumer demand for serums is increasing, there are still many people with sensitive skin who avoid serums altogether out of concern about possible skin irritation. Our new serums were formulated specifically to address this need: they support the skin barrier and deliver sustained, long-term benefits, while enhancing skin resilience over time and being gentle on the skin."

 

MATTHEW MECKFESSEL, PHD

DIRECTOR, MEDICAL AFFAIRS, GALDERMA

CETAPHIL VITAMIN C SERUM

Vitamin C formulas are known for their brightening, antioxidant capabilities, but irritation is a common concern for sensitive skin consumers. Cetaphil’s Vitamin C Serum is formulated with 3-O-ethyl ascorbic acid. This is a stable Vitamin C derivative that helps visibly reduce dark spots and defend against surface free radicals, while being gentle enough for daily use on sensitive skin.

  • Seven unique benefits: hydration, antioxidant protection, visibly evened tone and texture, boosted luminosity and visibly reduced dark spots and fine lines.
  • Combined with niacinamide to visibly brighten and even tone.

CETAPHIL CERAMIDE SERUM

Sensitive skin consumers are more prone to experiencing a damaged skin barrier. Cetaphil’s Ceramide Serum is a specifically formulated solution containing multiple key ingredients designed to support skin-barrier repair while soothing discomfort and reducing the appearance of redness. Cetaphil’s Ceramide Serum not only repairs the damaged skin barrier but helps to strengthen it over time.

  • Restorative formula clinically proven to lock in moisture for 48-hour hydration, leaving skin looking and feeling smooth, soft and hydrated.
  • Formulated with a blend of ceramide, centella asiatica and allantoin.
  • Clinically proven to decrease visible signs of dryness and roughness while visibly evening skin tone in three days.

Cetaphil Vitamin C Serum and Ceramide Serum are available now in the United States on Amazon.com and will be at major retailers beginning in August. See full list of retailers here: . For more information, consumers can also follow Cetaphil on ) and or visit .

About Cetaphil®

Over years ago, a leading pharmacist created the first Cetaphil product – a gentle, yet powerful formula that would clean without stripping and moisturize without clogging. Today, Cetaphil is a dermatologist recommended sensitive skincare brand and is recognized around the world. With the help of leading global skincare experts, they continue to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain skin’s health every day. For more information, visit .

About Galderma

Galderma (SIX: GALD) is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story.

For more information:

###

1 Circana (IRI): Walmart Customer Advantage Hierarchy, Walmart Face, 52 We 11/5/23; Kantar Skincare Usage Dynamics and Fundamentals Aug 2022.

2 Circana (IRI): Geography: Total U.S. – Multi Outlet; Time: Rolling 52 Weeks Ending 06-18-23.

3 Spate. Google Search data, year-over-year growth comparing search volume from November 2023 vs predicted search volume for November 2024 (US).

EN
09/07/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GALDERMA GROUP AG

 PRESS RELEASE

AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From I...

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SWX:GALD) will showcase a strong presence at the 23rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco from March 27-29, 2025, with two symposia, four Masterclass sessions, 11 research e-posters, and an experiential Galderma lounge alongside its interactive booth (O2, Hall Ravel) featuring five Meet-the-Expert sessions. This extensive program highlights the breadth of Galderma’s leading Injectable Aesthetics portfolio, designed to address the present and future needs of patients and healthcare professionals alike. This press release ...

 PRESS RELEASE

Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% ...

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2024, delivering strong results for another consecutive year while making significant progress with its blockbuster platforms and future growth drivers. Record net sales: Achieved 4,410 million USD in net sales, up 9.3% year-on-year on a constant currency basis1, with volume-based growth fueled by focused execution and differentiated innovation Broad-based growth: Continued performance across all product categories with constan...

 PRESS RELEASE

AAD 2025: Galderma to Present Extensive Updates From Across Its Dermat...

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma will present updates from across its broad dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 7-11, 2025 in Orlando, Florida. The company will present 22 e-posters – including two oral presentations – with updates on a number of its innovative products, including Nemluvio, Sculptra, Restylane and Relfydess. These presentations combined reinforce the strength of Galderma’s growth journey, its status as the pure-play category leader in dermatology, and its innovative pipeline. “We’re bring...

 PRESS RELEASE

Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in ...

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumab’s subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors in adults and adolescents 12 years of age and older with a body weight of at leas...

 PRESS RELEASE

Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for ...

ZUG, Switzerland--(BUSINESS WIRE)-- Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now approved for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.11 This press release features multimedia. View the full release...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch